Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment
Similar Posts
Scientific Protein Laboratories, LLC – 712578 – 10/10/2025
CGMP/Active Pharmaceutical Ingredient (API)/AdulteratedContinuous Ventilator (Respirator) Correction: Maquet Critical Care AB Updates Use Instructions for Servo Ventilator Systems Due to Risk of Inaccurate Compliance Measurement Leading to Improper Tidal Volume Delivery in Neonatal Patients
Maquet is updating Servo Ventilator instructions due to a risk of inaccurate tidal volume delivery when the extended leak test is used.Absolutely Natural – 715690 – 12/30/2025
CGMP/Finished Pharmaceuticals/AdulteratedEndothelin Receptor Antagonist REMS Information
FDA has determined that a REMS is no longer necessary to ensure ERA medicines’ benefits outweigh the risk of EFT.AnazaoHealth Corporation. Las Vegas, NV. 483 issued 08/08/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 08/08/2025
Short Title (70 char) AnazaoHealth Corporation. Las Vegas, NV. 483 issued 08/08/2025
FEI Number 3011152407
Firm Name AnazaoHealth Corporation
Record Type 483
State NV
Establishment Type Outsourcing FaRare Diseases at FDA
The FDA works with many people and groups, such as patients, caregivers, and drug and device manufactures, to support rare disease product development.